- Home
- TPST vs LVTX Comparison
TPST vs LVTX Comparison
Compare TPST & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- LVTX
- Stock Information
- Founded
- TPST 2011
- LVTX 2016
- Country
- TPST United States
- LVTX Netherlands
- Employees
- TPST N/A
- LVTX N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- LVTX Health Care
- Exchange
- TPST Nasdaq
- LVTX Nasdaq
- Market Cap
- TPST 33.0M
- LVTX 33.9M
- IPO Year
- TPST N/A
- LVTX 2021
- Fundamental
- Price
- TPST $7.09
- LVTX $1.31
- Analyst Decision
- TPST Hold
- LVTX Hold
- Analyst Count
- TPST 3
- LVTX 3
- Target Price
- TPST $30.00
- LVTX $1.75
- AVG Volume (30 Days)
- TPST 245.0K
- LVTX 34.5K
- Earning Date
- TPST 08-07-2025
- LVTX 08-19-2025
- Dividend Yield
- TPST N/A
- LVTX N/A
- EPS Growth
- TPST N/A
- LVTX N/A
- EPS
- TPST N/A
- LVTX N/A
- Revenue
- TPST N/A
- LVTX $4,990,000.00
- Revenue This Year
- TPST N/A
- LVTX N/A
- Revenue Next Year
- TPST N/A
- LVTX N/A
- P/E Ratio
- TPST N/A
- LVTX N/A
- Revenue Growth
- TPST N/A
- LVTX N/A
- 52 Week Low
- TPST $5.35
- LVTX $0.85
- 52 Week High
- TPST $30.03
- LVTX $2.39
- Technical
- Relative Strength Index (RSI)
- TPST 49.91
- LVTX 49.61
- Support Level
- TPST $6.87
- LVTX $1.28
- Resistance Level
- TPST $7.25
- LVTX $1.38
- Average True Range (ATR)
- TPST 0.67
- LVTX 0.05
- MACD
- TPST -0.02
- LVTX -0.00
- Stochastic Oscillator
- TPST 11.20
- LVTX 26.92
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.